Exposure-response (E-R) analysis of efficacy for avelumab in combination with axitinib in patients with advanced renal cell carcinoma (aRCC) in JAVELIN Renal 101.

被引：0
|
作者：
Bello, Carlo [1 ]
Brar, Satjit [1 ]
Masters, Joanna C. [2 ]
Khandelwal, Akash [3 ]
Novakovic, Ana M. [3 ]
Ruiz-Garcia, Ana [1 ]
Hibma, Jennifer [2 ]
机构：
[1] Pfizer Inc, San Diego, CA USA
[2] Pfizer Inc, La Jolla, CA USA
[3] Merck KGaA, Darmstadt, Germany
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1364
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab plus axitinib (A plus Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)
    Albiges, L.
    Rini, B. I.
    Haanen, J. B. A. G.
    Motzer, R. J.
    Kollmannsberger, C. K.
    Negrier, S.
    Nole, F.
    Bedke, J.
    Bilen, M. A.
    Nathan, P.
    Tomita, Y.
    Huang, B.
    Ching, K. A.
    Chudnovsky, A.
    Robbins, P. B.
    di Pietro, A.
    Thomaidou, D.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] Angiogenic and immunomodulatory biomarkers in axitinib-treated patients (pts) with advanced renal cell carcinoma (aRCC).
    Rini, Brian I.
    Escudier, Bernard
    Murphy, Danielle
    Wang, Panpan
    Tarazi, Jamal Christo
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [43] Characterizing Exposure-Response (E-R) Relationship of Safety for Nivolumab in Combination with Ipilimumab in Patients with Previously Untreated Advanced Melanoma
    Wang, Xiaoning
    Feng, Yan
    Statkevich, Paul
    Roy, Amit
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S37 - S38
  • [44] Exposure-Response (E-R) Analysis of Progression Free Survival (PFS) for Nivolumab in Combination with Ipilimumab in Patients with Previously Untreated Advanced Melanoma
    Feng, Yan
    Wang, Xiaoning
    Statkevich, Paul
    Roy, Amit
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S67 - S67
  • [45] Pharmacokinetics of Neoadjuvant Axitinib Influenced the Efficacy in Patients With Advanced Renal Cell Carcinoma
    Yamamoto, Yoshiaki
    Otori, Toru
    Inoue, Ryo
    Yano, Seiji
    Hirata, Hiroshi
    Matsumoto, Hiroaki
    Matsuyama, Kenji
    Matsuyama, Hideyasu
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (02): : 256 - 263
  • [46] Efficacy of avelumab plus axitinib for advanced renal cell carcinoma as late-line therapy: A case report
    Uekawa, Ayano
    Kurahashi, Ryoma
    Motoshima, Takanobu
    Murakami, Yoji
    Yatsuda, Junji
    Kamba, Tomomi
    UROLOGY CASE REPORTS, 2022, 45
  • [47] Exposure-response (E-R) efficacy and safety (E-S) analyses of tremelimumab as monotherapy or in combination with durvalumab in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
    Song Xuyang
    Kelley, Robin Kate
    Khan, Anis
    Standifer, Nathan
    Krishna, Rajesh
    Liu, Lucy
    Wang Kun
    Green, Michelle
    McCoon, Patricia
    Negro, Alejandra
    He, Philip
    Narwal, Rajesh
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [48] First-line avelumab plus axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.
    Choueiri, Toni K.
    Larkin, James M. G.
    Oya, Mototsugu
    Thistlethwaite, Fiona C.
    Martignoni, Marcella
    Nathan, Paul D.
    Powles, Thomas
    McDermott, David F.
    Robbins, Paul B.
    Chism, David D.
    Cho, Daniel C.
    Atkins, Michael B.
    Gordon, Michael S.
    Gupta, Sumati
    Uemura, Hirotsugu
    Tomita, Yoshihiko
    Compagnoni, Anna
    Di Pietro, Alessandra
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Efficacy of treatments post-lenvatinib in patients with advanced renal cell carcinoma (aRCC)
    Panian, Justine
    Zhong, Caiwei
    Choi, Sharon
    Quinn, Roxanne
    Ferrier, Evan
    Saad, Eddy
    Saliby, Renee Maria
    Malvar, Carmel
    Pal, Sumanta
    Ebrahimi, Hedyeh
    Tran, Ben
    Jude, Evon
    Lalani, Aly-Khan
    Suarez, Cristina
    De Velasco, Guillermo
    Kanesvaran, Ravindran
    Zarba, Martin
    Chehade, Razane El Hajj
    Choueiri, Toni K.
    Heng, Daniel
    McKay, Rana
    ONCOLOGIST, 2024, 29 : S23 - S23
  • [50] Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
    Tomita, Y.
    Motzer, R. J.
    Choueiri, T. K.
    Rini, B. I.
    Miyake, H.
    Oya, M.
    Albiges, L.
    Aizawa, M.
    Umeyama, Y.
    Wang, J.
    di Pietro, A.
    Schmidinger, M.
    ESMO OPEN, 2023, 8 (06)
12345